SCHEMBL2882729

SCHEMBL2882729

Cc1ccccc1C1CCN(C(=O)C2CCc3cccnc3C(=O)C2)CC1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRL1 P41146 6/20 0.68
KCNH2 Q12809 3/20 0.46
SMO Q99835 3/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
MGLL Q99685 1/20 0.39
TRPV1 Q8NER1 1/20 0.39
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
HSD11B1 P28845 1/20 0.38
AVPR1A P37288 1/20 0.38
RPLP1 P05386 1/20 0.37
RPLP0 P05388 1/20 0.37
RPS17 P08708 1/20 0.37
RPSA P08865 1/20 0.37
RPS2 P15880 1/20 0.37
RPL35A P18077 1/20 0.37
RPL7 P18124 1/20 0.37
RPL17 P18621 1/20 0.37
RPS4Y1 P22090 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2882732 0.85 OPRL1 (0.48) OPRL1SMOMGLLFNTAFNTB
SCHEMBL6501091 0.84 HTR7 (0.48) OPRL1KCNH2MEN1KMT2AMGLL
SCHEMBL2883175 0.84 OPRL1 (0.48) OPRL1KCNH2SMOMEN1KMT2A
SCHEMBL2877543 0.82 OPRL1 (0.48) OPRL1KCNH2MEN1KMT2AMGLL
SCHEMBL2885164 0.82 OPRL1 (0.48) OPRL1KCNH2MEN1KMT2AMGLL
SCHEMBL6076384 0.77 KMT2A (0.42) OPRL1KCNH2MEN1KMT2AMGLL
SCHEMBL6490761 0.77 OPRL1 (0.43) OPRL1KCNH2MEN1KMT2AMGLL
SCHEMBL6079726 0.75 KMT2A (0.40) OPRL1KCNH2MEN1KMT2AMGLL
SCHEMBL6075954 0.74 KMT2A (0.53) MEN1KMT2A
SCHEMBL6080691 0.74 OPRL1 (0.41) OPRL1KCNH2MEN1KMT2AMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7855294-B2 Cycloalkanopyridine derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-12-21 US disclosed
US-20070191419-A1 Cycloalkanopyridine derivative MSD K.K. (JP) 2007-08-16 US disclosed
EP-1726590-A1 CYCLOALKANOPYRIDINE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191419-A1 Cycloalkanopyridine derivative OPRL1, OPRK1, AVPR2 OPRL1 1/4885KCNH2 969/4885SMO 4843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.